Indeed, WT1 antibody therapies are showing promise in clinical trials for lung cancer, leukaemia, and other malignancies. Despite its emergence as a significant target in cancer therapy, our ...

in hrMSCs was linked to increased levels of a protein called Wilms Tumor Protein 1 (WT1), which triggers molecular changes ...

"Ovarian cancer is the leading cause of death from gynecologic ... Lower levels of AMP kinase led to higher levels of a ...

The full text of the abstract will be released by ASCO on May 22, 2025, at 5:00 PM EDT on asco.org/abstracts.

To address this serious limitation, CD8+ killer T cells were produced with specificity for the Wilms’ tumor antigen 1 (WT1), a cancer-promoting protein that is abnormally abundant in most cases of ...

One TCR-engineered immunotherapy targets Wilms’ tumor antigen 1 (WT1), a cancer-promoting protein that is abnormally expressed in myeloid leukemias and certain solid tumors. Dr. Chapuis recently ...

including Debiopharm International SA’s IAP inhibitor Debio 1143 (for ovarian cancer), SELLAS Life Sciences Group’s WT1 cancer vaccine (galinpepimut-S) (for acute myeloid leukaemia and ...